This study aimed to determine whether atomoxetine could effectively treat ADHD in children without worsening tic symptoms. The findings suggest that atomoxetine not only helps manage ADHD symptoms but also shows a trend towards reducing tic severity. This opens up new possibilities for those who have ADHD along with tic disorders.

The study challenges previous beliefs about traditional stimulant medications and highlights atomoxetine as a potential safer treatment option for these children.

The research involved children aged 7 to 17 diagnosed with both ADHD and either Tourette syndrome or chronic motor tic disorder. They were randomly assigned to receive either a placebo or atomoxetine, which is commercially sold as Strattera, over 18 weeks.

This double-blind approach means neither the subjects nor the researchers knew who received the medication versus the placebo, reducing bias in observed outcomes.

The results showed atomoxetine improved tic severity better than a placebo, indicated by scores on various scales evaluating tics. Notably, improvement was significant on the Clinical Global Impressions scale for tic severity. Improvements in ADHD symptoms were also notable, with more reduction in ADHD-related scales.

Though some side effects like increased heart rate and decreased appetite were noted, discontinuation rates were similar, suggesting atomoxetine's tolerability.

Atomoxetine did not worsen tic symptoms; in fact, there was evidence suggesting a reduction in tic severity alongside notable ADHD symptom improvement. This outcome emphasizes the medication's dual benefits.

Overall, atomoxetine was considered safe and tolerable, offering hope for patients needing treatment for both ADHD and tic disorders without escalating their tic conditions.